Floatz logo

Eloxatin

Extrahepatic Bile Duct Cancer

Lisata Therapeutics, Inc.Phase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Extrahepatic Bile Duct Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Lisata Therapeutics, Inc.
Phase 2BBB
Capecitabine
National Cancer Institute (NCI)
Phase 3BB
Irinotecan
AIO-Studien-gGmbH
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Lisata Therapeutics, Inc.
Phase 2BB
Carboplatin
University of Nebraska
Phase 1/2B

View all 47 →

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →